Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:49 2024-04-23 am EDT			5-day change	1st Jan Change
88.94 ^CHF	+1.81%		+4.64%	+4.80%

Apr. 23	US Equity Markets Close Higher Tuesday	MT
Apr. 23	Novartis Wins FDA Approval of Pancreatic Tumor Therapy in Children	MT

NOVARTIS AG : JP Morgan drops its Sell rating

January 03, 2023 at 04:14 am EST

JP Morgan's analyst Richard Vosser upgrades the rating on the company from Sell to Neutral. The target price has been revised upwards and is now set at CHF 85, compared with CHF 78 previously.

Latest news about Novartis AG

US Equity Markets Close Higher Tuesday	Apr. 23	MT
Novartis Wins FDA Approval of Pancreatic Tumor Therapy in Children	Apr. 23	MT
Novartis Gets FDA Approval for Lutathera in Pediatric Treatment	Apr. 23	DJ
Novartis radioligand therapy Lutathera(R) FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	Apr. 23	DJ
NOVARTIS : 2024 has started on a strong note; guidance upgraded	Apr. 23
Top Midday Stories: Shares of GE, Novartis, Danaher and Philip Morris Up Post-Earnings; Pepsi Stock Down Post-Earnings; Apple iPhone China Sales Drop 19%; Trump Poised for Windfall From Media Company Stock	Apr. 23	MT
Novartis’ Bumper Q1 Earnings Nudge Swiss Stocks Higher	Apr. 23	MT
Global markets live: Bayer, PepsiCo, Halliburton, Spotify, Apple...	Apr. 23
Corporate results bound the become the next catalyst for markets	Apr. 23
Dpa-AFX Overview: COMPANIES from 23.04.2024 - 15:15	Apr. 23	DP
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Apr. 23	MT
Trending : Novartis Shares Climb on Guidance Lift	Apr. 23	DJ
NOVARTIS AG : JP Morgan gives a Neutral rating	Apr. 23	ZD
Transcript : Novartis AG, Q1 2024 Earnings Call, Apr 23, 2024	Apr. 23
NOVARTIS AG : Barclays keeps a Sell rating	Apr. 23	ZD
Novartis Q1 Core Earnings, Net Sales Rise; 2024 Net Sales Outlook Updated	Apr. 23	MT
European Midday Briefing: Stocks Buoyed by Strong Earnings, FTSE 100 Hits Fresh Record	Apr. 23	DJ
North American Morning Briefing : Stock Futures Rise, Tesla Earnings in Focus	Apr. 23	DJ
NOVARTIS : Oddo BHF confirms its recommendation on the share	Apr. 23	CF
Novartis AG Revise Earnings Guidance for the Year 2024	Apr. 23	CI
MORNING BID AMERICAS-Tanking Tesla reports, Europe business beats	Apr. 23	RE
NOVARTIS AG : UBS remains its Buy rating	Apr. 23	ZD
Novartis Nominates Former Bristol Myers Squibb CEO as New Chair	Apr. 23	MT
Novartis Lifts 2024 Guidance as First-quarter Earnings Grow on Strong Blockbuster Drug Demand	Apr. 23	MT
NOVARTIS AG : Gets a Buy rating from Jefferies	Apr. 23	ZD

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

2024-07-18 - Q2 2024 Earnings Release

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 01:24 pm EDT

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

97.67 USD

Average target price

105.9 USD

Spread / Average Target

+8.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+4.80%	210B
ELI LILLY AND COMPANY	+27.92%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.59%	359B
MERCK & CO., INC.	+16.38%	322B
ABBVIE INC.	+9.39%	297B
ASTRAZENECA PLC	+6.30%	215B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.58%	149B
AMGEN INC.	-4.99%	146B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : JP Morgan drops its Sell rating

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals